ArticleInfection and drug resistance2025
Study on the Predictive Value of MASP-1 Combined with Four Thrombotic Molecular Markers for Disseminated Intravascular Coagulation in Patients with Severe Infection.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular biomarkers in dialysis-related thrombosis and anticoagulation monitoring: thrombin-antithrombin complex, plasmin-α2-antiplasmin complex, soluble thrombomodulin, tPA/PAI-1/tPAIC, and Anti-Xa.Frontiers in medicine · 2026Review
- Thrombomodulin as a Potentially Complementing Diagnostic Tool in Non-Pneumonic Bacterial Infections.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the predictive value of mannose-binding lectin-associated serine protease-1 (MASP-1) combined with four thrombotic molecular markers [thrombin-antithrombin complex (TAT), thrombomodulin (TM), plasmin-α2-plasmin inhibitor complex (PIC), and tissue-type plasminogen activator inhibitor complex (t-PAIC)] for disseminated intravascular coagulation (DIC) in patients with severe infection. Methods: Clinical data of 114 patients with severe infection admitted between January and December 2024 were retrospectively analyzed. Patients were divided into DIC (n=25) and non-DIC (n=89) groups per ISTH criteria. Serum MASP-1 (ELISA) and TAT, TM, PIC, t-PAIC (chemiluminescent immunoassay) levels were compared. Pearson correlation assessed relationships between MASP-1 and thrombotic markers. ROC curves evaluated diagnostic performance. Results: The expression levels of MASP-1, TAT, TM, PIC, and t-PAIC in Group A (with DIC) were significantly higher than those in Group B (without DIC) (P<0.05). Pearson correlation analysis showed that MASP-1 levels in patients with severe infection and DIC were positively correlated with TAT, TM, PIC, and t-PAIC levels (P<0.05). ROC curves showed that the area under the curve (AUC) for MASP-1, TAT, TM, PIC, t-PAIC, combined detection of thrombotic molecular markers, and MASP-1 combined with thrombotic molecular markers were 0.714, 0.739, 0.692, 0.684, 0.776, and 0.835, respectively. The diagnostic efficacy of MASP-1 combined with thrombotic molecular markers was superior to MASP-1, TAT, TM, PIC, t-PAIC alone or thrombotic molecular markers combined alone (Z MASP-1+thrombotic markers combined-MASP-1, TAT, TM, PIC, t-PAIC and thrombotic markers combined = 3.637, 3.152, 4.126, 3.974, 4.383, and 2.975, P<0.05). Conclusion: This retrospective study suggests that MASP-1 correlates with thrombotic marker expression in severe infection. The combination of MASP-1 and thrombotic markers shows promise for improving early DIC diagnosis, but its clinical utility warrants confirmation by larger, prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.